Intravenous immunoglobulin showed no clear difference in significant improvement in disability within 6 weeks compared with prednisolone (moderate certainty).
It is very uncertain whether intravenous immunoglobulin changes event‐free survival (risk of death, cardiac transplant, or left… compared with placebo or no treatment (very low certainty).
It is very uncertain whether intravenous immunoglobulin changes overall survival (risk of death) ‐ adults with myocarditis, median compared with placebo or no treatment (very low certainty).
It is very uncertain whether intravenous immunoglobulin changes side effects ‐ mild infusion effects, 12‐month compared with placebo or no treatment (very low certainty).
It is very uncertain whether intravenous immunoglobulin changes overall survival (risk of death) ‐ children with myocarditis, 6‐month compared with placebo or no treatment (very low certainty).
It is very uncertain whether hepatitis B immunoglobulin (HBIG) changes newborn with HBsAg‐positive result compared with no intervention (very low certainty).
It is very uncertain whether hepatitis B immunoglobulin (HBIG) changes newborn with HBeAg‐positive result compared with no intervention (very low certainty).
Hepatitis B immunoglobulin (HBIG) may leads to lower newborn with HBV‐DNA‐positive result compared with no intervention (low certainty).
It is very uncertain whether summary of findings table ‐ Immunoglobulins changes mortality (any cause during hospitalisation or compared with placebo (very low certainty).
Summary of findings table ‐ Immunoglobulins showed no clear difference in adverse events of any severity or seriousness compared with placebo (low certainty).
Summary of findings table ‐ Immunoglobulins showed no clear difference in serious adverse events compared with placebo (low certainty).
Hyperimmune immunoglobulin from human plasma showed no clear difference in all‐cause mortality at day 28 compared with saline placebo (low certainty).
It is very uncertain whether hyperimmune immunoglobulin from human plasma changes worsening of clinical status at day 28 (data only available for… compared with saline placebo (very low certainty).
Hyperimmune immunoglobulin from human plasma showed no clear difference in improvement of clinical status (number of people discharged from… compared with saline placebo (moderate certainty).
The review found no eligible studies for this question.
Hyperimmune immunoglobulin from human plasma showed no clear difference in adverse events of any grade up to 28 days (data only available for… compared with saline placebo (low certainty).